Neuro-Oncology · 2014 · 77 citations · 13 references
MedicineOncologyPathologyCancer GeneticsPrecision MedicinePrecision OncologyDisease ModelingGenetic Risk PredictionGlioblastomaMolecular Classification Of TumorsMolecular Tumor ProfilingTumor ClassificationCancer Risk Prediction ModelsExternal Validation CohortsGlioma GradingIsocitrate Dehydrogenase MutationsLogistic RegressionMultivariable Regression AnalysisMutationPredictive Model Validation
BACKGROUND: Several variables are associated with the likelihood of isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation in gliomas, though no guidelines yet exist for when testing is warranted, especially when an R132H IDH1 immunostain is negative. METHODS: A cohort of 89 patients was used to build IDH1/2 mutation prediction models in World Health Organization grades II-IV gliomas, and an external cohort of 100 patients was used for validation. Logistic regression and backward model selection with the Akaike information criterion were used to develop prediction models. RESULTS: A multivariable model, incorporating patient age, glioblastoma multiforme diagnosis, and prior history of grade II or III glioma, was developed to predict IDH1/2 mutation probability. This model generated an area under the curve (AUC) of 0.934 (95% CI: 0.878, 0.978) in the external validation cohort and 0.941 (95% CI: 0.918, 0.962) in the cohort of The Cancer Genome Atlas. When R132H IDH1 immunostain information was added, AUC increased to 0.986 (95% CI: 0.967, 0.998). This model had an AUC of 0.947 (95% CI: 0.891, 0.995) in predicting whether an R132H IDH1 immunonegative case harbored a less common IDH1 or IDH2 mutation. The models were also 94% accurate in predicting IDH1/2 mutation status in gliomas from The Cancer Genome Atlas. An interactive web-based application for calculating the probability of an IDH1/2 mutation is now available using these models. CONCLUSIONS: We have integrated multiple variables to generate a probability of an IDH1/2 mutation. The associated web-based application can help triage diffuse gliomas that would benefit from mutation testing in both clinical and research settings.
13
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang, David W. White, Bryson D. Bennett et al. · Nature · 2009 · 4.1K citations · Full text
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
David Capper, Susanne Weißert, Antje Habel et al. · Brain Pathology · 2009 · 523 citations · Full text
Monoclonal antibody specific for IDH1 R132H mutation
David Capper, Hanswalter Zentgraf, Christian Hartmann et al. · Acta Neuropathologica · 2009 · 431 citations
Ovidiu C. Andronesi, Grace S. Kim, Elizabeth R. Gerstner et al. · Science Translational Medicine · 2012 · 421 citations
Medicine, Biochemistry, Oncology +17